Evommune, Inc.
NYSE:EVMNBiotechnology
Healthcare
$6.88 -0.82%
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
52W Low $13.89High $33.20
Volume 0.60M
Average 0.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$76.44M
FY 2025 · Annual
Investing Cash Flow
-$115.31M
FY 2025 · Annual
Financing Cash Flow
$220.76M
FY 2025 · Annual
+346.7% YoYCash Flow Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$68.9M
+ D&A$1.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$4.1M
- Other Non-Cash-$4.8M
= Operating Cash Flow-$76.4M
- Capex-$235.0K
= Free Cash Flow-$76.7M
Analysis
FY2025 free cash flow is -$76.7M. FCF conversion is 111.3% of net income. Operating cash flow was -$76.4M, with capex of -$235.0K. The largest bridge item is Other Non-Cash at -$4.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B3 | 424B3 filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does EVMN generate free cash flow?
Evommune, Inc. (EVMN) generated -$76.68M of free cash flow in fiscal 2025.
How much operating cash flow does EVMN produce?
Operating cash flow was -$76.44M, before capital expenditures of $235,000.00.
Continue the stock analysis
Jump to another research area for this company.